person · Reporting owner

Jovan-Embiricos Morana

Disclosed activity across 3 companies

Tapewire entity: 41364
SEC CIK: 0001575745

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kalaris Therapeutics, Inc.KLRS · Entity 6805	Director	June 03, 2026	June 04, 2026
TCR2 THERAPEUTICS INC.TCRR · Entity 94327	10% owner	December 18, 2019	December 20, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02	Direct	9,000	Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

TCR2 THERAPEUTICS INC.

Report date December 18, 2019 · Filed December 20, 2019

Jointly reported with Globeways Holdings Ltd, Globeways Holdings II Ltd, F2 Capital I 2015 Ltd, F2 Captial I 2017 Ltd, F2 MG Ltd, F2 Bioscience II 2017 Ltd, F2 - TPO Investments LLC, F2 BBG LLC, F2 Capital I 2019, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Fund	89,217	Reported balance After 2019-12-18 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2019-12-18 · Sale · Disposed 458 · Balance 89,217 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	191,309	Reported balance After 2019-12-18 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2019-12-18 · Sale · Disposed 2,433 · Balance 191,309 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	82,575	Reported balance After 2019-12-19 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2019-12-19 · Sale · Disposed 6,642 · Balance 82,575 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	155,986	Reported balance After 2019-12-19 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2019-12-19 · Sale · Disposed 35,323 · Balance 155,986 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	713,723	Reported balance After 2019-12-20 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2019-12-20 · Other · Disposed 586,153 · Balance 713,723 F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	161,024	Reported balance After 2019-12-20 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2019-12-20 · Other · Disposed 13,847 · Balance 161,024 F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	361,665	Reported balance Holding disclosure · report date 2019-12-18 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 361,665 F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	432,319	Reported balance Holding disclosure · report date 2019-12-18 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 432,319 F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	330,238	Reported balance Holding disclosure · report date 2019-12-18 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 330,238 F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.

F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.

F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cullinan Therapeutics, Inc.

Report date August 02, 2022 · Filed August 05, 2022

Jointly reported with F2 Vision SCS

Section 16 reporting ended · disclosed 2022-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,255,963	Last balance in matching sequence After 2022-08-04 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-08-02 · Sale · Disposed 4,792 · Balance 1,301,081 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Row 2 · 2022-08-03 · Sale · Disposed 19,129 · Balance 1,281,952 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Row 3 · 2022-08-04 · Sale · Disposed 25,989 · Balance 1,255,963 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Globeways Holdings Ltd.	1,136,525	Reported balance Holding disclosure · report date 2022-08-02 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,136,525 F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 Bioscience I 2017 Ltd.	537,392	Reported balance Holding disclosure · report date 2022-08-02 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 537,392 F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 MG Ltd.	325,333	Reported balance Holding disclosure · report date 2022-08-02 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 325,333 F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2-TPO Investments, LLC	622,175	Reported balance Holding disclosure · report date 2022-08-02 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 622,175 F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 Bio TD, LLC	71,599	Reported balance Holding disclosure · report date 2022-08-02 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 71,599 F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 MC, LLC	214,798	Reported balance Holding disclosure · report date 2022-08-02 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 214,798 F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 GC, LLC	104,762	Reported balance Holding disclosure · report date 2022-08-02 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 104,762 F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Morana Jovan-Embiricos	207,803	Reported balance Holding disclosure · report date 2022-08-02 · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · Balance 207,803 F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 23, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	683	$17.31	$11,823.69	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 174,871 F2 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 23, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	1,535	$17.31	$26,573.00	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 392,765 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	197,343	$17.94	$3,539,425.64	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,417,172 F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	50,134	$17.94	$899,173.34	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 360,034 F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	65,633	$17.94	$1,177,154.11	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 471,299 F4 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	12,537	$17.94	$224,856.11	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 90,026 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	24,446	$17.94	$438,448.79	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 175,554 F2 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:27 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	54,907	$17.94	$984,779.01	Disclosure SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 394,300 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 04, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	12,214	$17.55	$214,414.33	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 102,563 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
September 03, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	10,559	$17.01	$179,652.94	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 114,777 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 29, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	3,700	$17.01	$62,925.16	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 125,336 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 28, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	6,700	$17.01	$113,940.87	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 129,036 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 27, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	1,200	$17.01	$20,413.56	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 135,736 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 26, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	29,128	$17.01	$495,478.93	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 136,936 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 23, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	3	$17.00	$51.00	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 166,064 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 22, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	100	$17.03	$1,703.00	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 166,067 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2019 Filed Sep 5, 2019 16:32 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	SaleCommon Stock	500	$17.00	$8,500.00	Disclosure SEC source: 0000899243-19-022834 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 166,167 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionSeries B Preferred Stock · Derivative	2,500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 14 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 403,629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionSeries B Preferred Stock · Derivative	1,750,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 13 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 282,540 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionSeries B Preferred Stock · Derivative	2,540,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 410,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionSeries B Preferred Stock · Derivative	1,200,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 193,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F4 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionSeries A Preferred Stock · Derivative	10,000,001	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 1,614,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	PurchaseCommon Stock	133,333	$15.00	$1,999,995.00	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 536,962 F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	PurchaseCommon Stock	166,667	$15.00	$2,500,005.00	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 449,207 F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	PurchaseCommon Stock	166,667	$15.00	$2,500,005.00	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 166,667 F9 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	PurchaseCommon Stock	200,000	$15.00	$3,000,000.00	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 200,000 F8 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionCommon Stock	403,629	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 403,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionCommon Stock	282,540	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 282,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionCommon Stock	410,168	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 410,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionCommon Stock	193,742	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 193,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F4 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 21, 2019 17:01 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	ConversionCommon Stock	1,614,515	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,614,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.